1
|
Reuillard A, Combaret N, Garrouste C, Azarnoush K, Aniort J, Pereira B, Innorta A, Souteyrand G. Impact sur la fonction rénale du traitement curatif d’un rétrécissement aortique serré chez les patients insuffisants rénaux chroniques. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Gandji W, Azarnoush K, Mulliez A, Innorta A, Farhat M, Combaret N, Durel N, Souteyrand G, Lusson JR, Camilleri L. [Impact of transcatheter aortic valve implantation in the treatment of aortic valve disease after previous coronary artery bypass]. Ann Cardiol Angeiol (Paris) 2015; 65:7-14. [PMID: 25641084 DOI: 10.1016/j.ancard.2015.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Accepted: 01/02/2015] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Patients with a history of coronary artery bypass and aortic valve disease constitute a high-risk group for conventional redo surgery. The transcatheter aortic valve implantation (TAVI) may be an alternative for high-risk patients. The purpose of this study is to evaluate the impact of TAVI in the treatment of aortic valve disease after previous surgical coronary artery revascularization. PATIENTS AND METHODS This is a single-center retrospective, observational study, including 87 patients undergoing surgery for surgical heart valve replacement or TAVI from January 2007 to December 2013. RESULTS The introduction of transcatheter aortic valve implantation techniques has doubled the number of redo patients treated for aortic valve disease. From 2010 to 2013, the patients treated by conventional surgery diminished by 30%, with improved postoperative outcomes. This study allowed us to notice differences in patient's in terms of operative risk factors. For the same reasons no comparison was possible between 2 subgroup of patients. Hospital mortality was 6.4% for conventional aortic surgery and 20% for transcatheter aortic valve treatment. CONCLUSION Surgery remains the standard treatment for aortic valve disease even in redo patients, but TAVI becomes a very interesting tool as it may represent a tailored approach for our patients.
Collapse
Affiliation(s)
- W Gandji
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - K Azarnoush
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France; Inra, UMR 1019 nutrition humaine, 63122 Saint-Genès-Champanelle, France.
| | - A Mulliez
- Bio-statistics unit, délégation recherche clinique & innovation. CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - A Innorta
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - M Farhat
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - N Combaret
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - N Durel
- Service de cardiologie, pôle santé république, 105, avenue de la République, 63050 Clermont-Ferrand, France
| | - G Souteyrand
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - J R Lusson
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| | - L Camilleri
- Pôle cardiologie médicale et chirurgicale, CHU de Clermont-Ferrand, place H.-Dunant, B.P. 69, 63000 Clermont-Ferrand, France
| |
Collapse
|